drugset / Trial / NCT06390748
Esmolol in Sepsis Management:Evaluating Immunomodulatory Effects and Impact on Patient Outcomes
RandomizedParallel-groupSingle-blindTreatment
Summary
Evaluate the effectiveness of esmolol, a selective β1-adrenergic receptor blocker, in modulating immune responses and improving patient outcomes in sepsis.
Timeline
- Start
- 2021-01-01
- Primary completion
- 2023-12-31
- Completion
- 2023-12-31
Publications
- Results Pedicino D, Volpe M. beta1-Adrenergic receptor stimulation modulates immune response in cancer: a role for beta-blockers in antineoplastic treatment? Eur Heart J. 2024 Mar 14;45(11):870-871. doi: 10.1093/eurheartj/ehae008. No abstract available.
- Jing D, Xiong L, Zhang R, Fang H, Chen L. Esmolol improves sepsis outcomes through cardiovascular and immune modulation. Front Pharmacol. 2025 May 12;16:1498227. doi: 10.3389/fphar.2025.1498227. eCollection 2025.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Esmolol | Other / unclassified | — | — |